NASDAQ:XENEXenon Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.22 -0.69 (-5.34 %) (As of 06/3/2020 03:36 PM ET) Add Compare Share Today's Range$12.05Now: $12.23▼$13.0050-Day Range$11.90MA: $13.15▼$14.9052-Week Range$7.00Now: $12.23▼$18.45Volume585,602 shsAverage Volume156,476 shsMarket Capitalization$427.51 millionP/E RatioN/ADividend YieldN/ABeta1.36 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingXenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.67, Xenon Pharmaceuticals has a potential upside of 93.6% from its current price of $12.23.Amount of Analyst CoverageXenon Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesXenon Pharmaceuticals has received 353 “outperform” votes. (Add your “outperform” vote.)Underperform VotesXenon Pharmaceuticals has received 293 “underperform” votes. (Add your “underperform” vote.)Community SentimentXenon Pharmaceuticals has received 54.64% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote “Outperform” if you believe XENE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $113,240.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Xenon Pharmaceuticals is held by insiders.Percentage Held by Institutions79.24% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($0.88) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -9.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -9.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XENE Previous Symbol CUSIPN/A CIK1582313 Webwww.xenon-pharma.com Phone604-484-3300Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.82Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.83 million Price / Sales62.59 Cash FlowN/A Price / Cash FlowN/A Book Value$2.99 per share Price / Book4.09Profitability EPS (Most Recent Fiscal Year)($1.54) Net Income$-41,600,000.00 Net MarginsN/A Return on Equity-37.15% Return on Assets-25.60%Miscellaneous Employees89 Outstanding Shares34,970,000Market Cap$427.51 million Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:XENE Rates by TradingView Receive XENE News and Ratings via Email Sign-up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions How has Xenon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XENE stock has decreased by 3.8% and is now trading at $12.2250. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Xenon Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Xenon Pharmaceuticals. When is Xenon Pharmaceuticals' next earnings date? Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Xenon Pharmaceuticals. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc (NASDAQ:XENE) posted its quarterly earnings data on Thursday, May, 21st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.10. The biopharmaceutical company had revenue of $7.08 million for the quarter, compared to analyst estimates of $7.50 million. View Xenon Pharmaceuticals' earnings history. What price target have analysts set for XENE? 4 brokerages have issued 12-month target prices for Xenon Pharmaceuticals' shares. Their forecasts range from $23.00 to $25.00. On average, they expect Xenon Pharmaceuticals' stock price to reach $23.67 in the next twelve months. This suggests a possible upside of 93.6% from the stock's current price. View analysts' price targets for Xenon Pharmaceuticals. Has Xenon Pharmaceuticals been receiving favorable news coverage? Media coverage about XENE stock has trended very negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xenon Pharmaceuticals earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutXenon Pharmaceuticals. Who are some of Xenon Pharmaceuticals' key competitors? Some companies that are related to Xenon Pharmaceuticals include SAGE Therapeutics (SAGE), Ligand Pharmaceuticals (LGND), Passage Bio (ZNTL), Epizyme (EPZM), Madrigal Pharmaceuticals (MDGL), Xencor (XNCR), Y-mAbs Therapeutics (YMAB), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Heron Therapeutics (HRTX), Zogenix (ZGNX), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Opko Health (OPK) and Ironwood Pharmaceuticals (IRWD). View all competitors. What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Viking Therapeutics (VKTX), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Arbutus Biopharma (ABUS), Crispr Therapeutics (CRSP) and Dynavax Technologies (DVAX). Who are Xenon Pharmaceuticals' key executives? Xenon Pharmaceuticals' management team includes the following people: Simon Neil Pimstone, Chief Executive Officer & DirectorIan C. Mortimer, President, Chief Financial Officer & SecretaryErnesto Aycardi, Chief Medical OfficerRobin Sherrington, Executive VP-Business & Corporate DevelopmentCharles J. Cohen, Vice President-Biological Sciences What is Xenon Pharmaceuticals' stock symbol? Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE." Who are Xenon Pharmaceuticals' major shareholders? Xenon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (4.76%), Bank of New York Mellon Corp (1.93%), Rock Springs Capital Management LP (1.43%), Driehaus Capital Management LLC (1.32%), Ikarian Capital LLC (1.27%) and Vivo Capital LLC (1.13%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone. View institutional ownership trends for Xenon Pharmaceuticals. Which institutional investors are selling Xenon Pharmaceuticals stock? XENE stock was sold by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., Squarepoint Ops LLC, JPMorgan Chase & Co., Falcon Point Capital LLC, and State Street Corp. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, Mohammad Azab, and Simon N Pimstone. View insider buying and selling activity for Xenon Pharmaceuticals. Which institutional investors are buying Xenon Pharmaceuticals stock? XENE stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Rock Springs Capital Management LP, Driehaus Capital Management LLC, Bank of New York Mellon Corp, Vivo Capital LLC, Ghost Tree Capital LLC, Ikarian Capital LLC, and Burrage Capital Management LLC. View insider buying and selling activity for Xenon Pharmaceuticals. How do I buy shares of Xenon Pharmaceuticals? Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Xenon Pharmaceuticals' stock price today? One share of XENE stock can currently be purchased for approximately $12.23. How big of a company is Xenon Pharmaceuticals? Xenon Pharmaceuticals has a market capitalization of $427.51 million and generates $6.83 million in revenue each year. The biopharmaceutical company earns $-41,600,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe. What is Xenon Pharmaceuticals' official website? The official website for Xenon Pharmaceuticals is www.xenon-pharma.com. How can I contact Xenon Pharmaceuticals? Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected] This page was last updated on 6/3/2020 by MarketBeat.com Staff
